Acyclovir News
- BioAlliance Pharma SA announces the grant of its main patent on the Lauriad(R) technology in Europe (Marketwire via Yahoo! Finance)
BioAlliance Pharma announces the grant of its main patent on the Lauriad® technology in Europe - BioAlliance Pharma SA appoints Pierre MORGON Chief Operating Officer (Marketwire via Yahoo! Finance)
BioAlliance Pharma SA, the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced that it has strengthened its Management Board with the appointment of Pierre MORGON as Chief Operating Officer (COO). - YOU ARE HERE: (Aidsmap)
In a series of oral presentations at the XVII International AIDS Conference last week, investigators presented data from several trials on whether continuous use of aciclovir to suppress HSV-2 infection could curb HIV transmission. - BioAlliance Pharma Complements Its Portfolio with a European License for Ondansetron RapidFilm(TM) (Finanzen.net)
Regulatory News: BioAlliance Pharma SA. (Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, and APR Applied Pharma Research SA., together with its joint venture ... - Local fibromyalgia support groups are hard to find (Anderson Independent-Mail)
If you?re interested in helping individuals with fibromyalgia, you might consider organizing a support group in your area - BioAlliance Pharma SA complements its portfolio with a European license for ondansetron RapidFilm(TM) (Marketwire via Yahoo! Finance)
BioAlliance Pharma complements its portfolio with a European license for ondansetron RapidFilm(TM) - Genital herpes treatment does not prevent HIV (Reuters via Yahoo! News)
Long-term treatment of genital herpes with the drug acyclovir does not reduce the rate of new HIV infections, researchers reported at the International AIDS Conference here last week. - BioAlliance Pharma appoints Pierre MORGON Chief Operating Officer and Member of the Management Board (wallstreet:online AG)
Regulatory News: BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused